Research Library

A 15 amino acid peptide fragment based on a sequence in human gastric juice, studied extensively for tissue repair and angiogenic signaling in preclinical models.

The synthetic actin binding fragment (LKKTETQ) of thymosin beta-4, studied for cell migration, angiogenesis, and systemic tissue repair in animal models.

A naturally occurring copper binding tripeptide first isolated from human plasma, investigated for collagen synthesis, tissue remodeling, and broad gene expression modulation.

The C terminal tripeptide of α MSH, studied for anti inflammatory activity via NF-κB modulation, without the melanocortin or tanning effects of the parent hormone.

A co formulated three peptide research blend of GHK-Cu, BPC-157, and TB-500, positioned for multi pathway tissue repair and skin quality research.

A stabilized synthetic analog of GHRH(1-44) that resists DPP-IV degradation, FDA approved to reduce excess visceral abdominal fat in HIV associated lipodystrophy.

A GHRH analog paired with a selective ghrelin receptor agonist, combined to synergistically stimulate pulsatile growth hormone release.

The GHRH(1-29) fragment, the shortest fully active GHRH sequence, used to stimulate physiologic, pulsatile growth hormone secretion.

An orally active non peptide ghrelin receptor agonist that reliably raises GH and IGF-1, studied across GH deficiency, sarcopenia, and aging, with a notable cardiac safety flag.

A family of synthetic ghrelin mimetic GH releasing peptides acting on GHS-R1a, varying in GH potency, appetite stimulation, and cortisol/prolactin effect.

A cell permeable tetrapeptide that binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae and improving bioenergetics, the first drug to directly target mitochondria.

A synthetic tetrapeptide (Ala-Glu-Asp-Gly) analog of the pineal peptide epithalamin, studied for telomerase activation and pineal/melatonin rhythm regulation in aging models.

A short chain tripeptide bioregulator (Glu-Asp-Arg) from the Khavinson program, studied for neuroprotection and a proposed, but under validated, direct gene promoter binding mechanism.

A dinucleotide coenzyme (not a peptide) central to mitochondrial energy, DNA repair, and sirtuin signaling, which declines with age, the basis for the supplementation rationale.

A 16-amino acid peptide encoded by the mitochondrial 12S rRNA gene, discovered as a signaling molecule that activates AMPK to regulate metabolism and insulin sensitivity.

The first identified mitochondrial derived peptide, cytoprotective and anti apoptotic via AKT/ERK/STAT3 signaling in preclinical neuronal and vascular models.

A 28-amino acid thymic peptide that modulates innate and adaptive immunity via TLR signaling, one of the most clinically tested peptides in existence.

A synthetic heptapeptide analog of ACTH(4-10) with CNS activity but no corticotropic effect, used in Russia as a nootropic/neuroprotective agent.

A synthetic heptapeptide analog of tuftsin studied as a non sedating anxiolytic, modulating GABA/serotonin systems and raising BDNF without dependence in studied models.

An angiotensin IV analog reported in preclinical models to be a potent procognitive/synaptogenic compound acting via HGF/c-Met signaling.

A topical collagen 'signal' peptide (palmitoyl pentapeptide-4) that prompts fibroblasts to synthesize collagen, among the best studied cosmetic peptides.

A topical hexapeptide (acetyl hexapeptide-3/8) that interferes with SNARE complex formation, a mild, 'topical Botox like' approach to expression wrinkles.

A cyclic heptapeptide melanocortin (MC4R) agonist that acts centrally on sexual desire circuitry, FDA approved as Vyleesi for premenopausal HSDD.

A once weekly triple agonist of the GLP-1, GIP, and glucagon receptors, the glucagon arm distinguishing it from dual agonists by raising energy expenditure.

A modified C terminal fragment of growth hormone (176-191) intended to isolate GH's fat burning action without raising IGF-1 or affecting blood glucose.

A long acting IGF-1 analog engineered to evade binding proteins, driving IGF-1R signaling and muscle hypertrophy, with the steepest risk profile in this library.